Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Deucravacitinib Tablet vs Capsule and Food Effect
NCT03254784Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of deucravacitinib in systemic lupus erythematosus (SLE), psoriatic arthritis (PsA), psoriasis and 1 more (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at 5 days, AUC from time zero extrapolated to infinity at 5 days and 2 more. Started Sep 2017; status: completed.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)psoriatic arthritis (PsA)psoriasisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03254784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254784.